Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$460.00
|
|
Provider: Edison Investment Research
|
$10.00
|
|
Provider: Edison Investment Research
|
$10.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
4 SC AG Announces Restructuring and Layoffs
4 SC AG announced that due to changes in the personnel structure, mainly concerning aspects of preclinical and early clinical development, as well as in administration restructuring, the Ueberlingen-Bonndorf office will be closed. This will reduce the number of employees from 84 (as at May 31, 2013) by 13% or 15% over the course of 2013.
Latest Developments for 4 SC AG
- 4 SC AG Gives Update On Clinical Development Of Lead Cancer Compound Resminostat
- 4 SC AG's CEO and Chairman of Management Board Resigns
- 4SC AG Reports Positive Data from Clinical Phase I Trial with 4SC-205 in Cancer Patients and Initiates Study Amendment to Further Investigate the Compound
- 4SC AG Comments on Capital Increase
Latest Key Developments in Biotechnology
- Biogen Idec Inc And Swedish Orphan Biovitrum AB Presents New Data From Phase 3 Study Of Long-Lasting Hemophilia Factor Candidate ALPROLIX
- Novation Holdings Inc Announces Acquisition Of Controlling Interest In Solar Energy Initiatives Inc
- La Jolla Pharmaceutical Co Announces FDA Acceptance Of IND For LJPC-501
- Portola Pharmaceuticals Inc Announces Positive Phase 2 Study Results Showing Factor Xa Inhibitor Antidote PRT4445 Reverses Anticoagulant Activity Of Eliquis
- Share this
- Link this
- Digg this
Follow Reuters